{"id":"NCT00720382","sponsor":"Meda Pharmaceuticals","briefTitle":"A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis","officialTitle":"Active Controlled Trial of the Safety and Tolerability of MP 03-036 (Astepro 0.15%) in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2008-06","completion":"2008-07","firstPosted":"2008-07-22","resultsPosted":"2010-01-15","lastUpdate":"2015-05-21"},"enrollment":703,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Perennial Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"0.15% azelastine hydrochloride","otherNames":[]},{"type":"DRUG","name":"Mometasone furoate","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.","primaryOutcome":{"measure":"Change From Baseline on Direct Visual Nasal Exams to 12 Months","timeFrame":"Change from baseline to 12 months","effectByArm":[{"arm":"Astepro 0.15%","deltaMin":466,"sd":null},{"arm":"NasonexÂ®","deltaMin":237,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":12},"locations":{"siteCount":59,"countries":["United States"]},"refs":{"pmids":["39885937"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":466},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","HEADACHE","EPISTAXIS","DYSGEUSIA","NASAL DISCOMFORT"]}}